

**Press release 9 June, 2008**

## **Orexo strengthens the Executive Management Group**

*Orexo recruits Robin Wright, with extensive experience from international corporate finance and business development in the pharmaceutical and life science sector, as responsible for Business & Commercial Development. Robin Wright will be part of Orexo's Executive Management Group.*

Robin Wright joins from BioScience Managers Limited, a specialist healthcare fund manager and corporate finance boutique, where he held the position as Head of Corporate Advisory Services. Robin has extensive experience in providing financial and strategic advice and idea generation for life science companies. Göran Smedegård, previously responsible for Business & Commercial Development, leaves his position at Orexo but will continue to work as a consultant for the company.

Orexo has also made some additional changes to the Executive Management Group. Göran Tornling, Head of R&D, leaves Orexo and his responsibilities are divided into two areas, pre-clinical research and development and clinical and pharmaceutical development. Charlotte Edenius will be responsible for pre-clinical research and development and joins the executive management group. Thomas Lundqvist, member of the Executive Management, will be responsible for clinical and pharmaceutical development.

“We are delighted over the recruitment of Robin Wright. He has demonstrated success in over 130 transactions in over 40 countries. Robin is indeed a skilled principal negotiator with excellent marketing and execution skills. Robin has a perfect profile for us in our continued work to develop Orexo and find future partners. The strengthening of the Executive Management Group is another step in becoming a profitable pharma company. I would also like to thank Göran Tornling for his excellent contributions to Orexo and wish him all the best in his future endeavours”, says Torbjörn Bjerke, President and CEO, Orexo AB.

### **For more information, please contact:**

Torbjörn Bjerke, President and CEO, Orexo AB

Tel: +46 (0)708-66 19 90

E-mail: [torbjorn.bjerke@orexo.com](mailto:torbjorn.bjerke@orexo.com)

Claes Wenthzel, Executive Vice President & CFO, Orexo AB

Tel: +46 (0)18-780 88 44

E-mail: [claes.wenthzel@orexo.com](mailto:claes.wenthzel@orexo.com)

## TO THE EDITORS

### About Orexo

Orexo is a pharmaceutical company, focusing on development of new, patented drugs by combining well-documented substances with innovative technologies, and the development of new treatments for respiratory and inflammatory diseases.

Orexo has a broad and competitive late-stage product portfolio, including two marketed products, five products in clinical phase and two undergoing registration.

To date, Orexo have out-licensed the market rights for Rapinyl for the US, the EU and Japan markets, the world-wide market rights for Sublinox (OX22) and OX-NLA, and a out-license and research collaboration with Boehringer Ingelheim regarding the development of a new class of drugs to treat pain and inflammation. Also, Orexo has established a Nordic sales force by entering into a joint venture with ProStrakan.

Orexo has head office in Uppsala and is listed on the OMX Nordic Exchange Stockholm, Small Cap (ticker: ORX).

[www.orexo.com](http://www.orexo.com)